Ofatumumab
Generic name: ofatumumab [ OH-fa-TOO-mue-mab ]
Brand names: Arzerra, Kesimpta
Dosage forms: intravenous solution (20 mg/mL); subcutaneous solution (20 mg/0.4 mL)
Drug classes:CD20 monoclonal antibodies, Selective immunosuppressants
What is ofatumumab?
This leaflet provides information about two different brands of ofatumumab.
Arzerra is used to treat chronic lymphocytic leukemia (CLL), sometimes in combination with other cancer medicines.
Kesimpta is used to treat relapsing forms of multiple sclerosis in adults (including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease).
Ofatumumab may also be used for purposes not listed in this medication guide.
Warnings
Ofatumumab may cause a serious brain infection that can lead to disability or death. Call your doctor right away if you have problems with speech, thought, vision, or muscle movement.
If you've ever had hepatitis B, using ofatumumab can cause this virus to become active or get worse. Tell your doctor if you don't feel well and you have right-sided upper stomach pain, vomiting, loss of appetite, or yellowing of your skin or eyes.
Before taking this medicine
You should not use Kesimpta if you have active hepatitis B.
Tell your doctor if you have ever had:
an active or chronic infection;
a condition for which you have used an immunosuppressant medication; or
hepatitis B.
You may need to take antiviral medicine if you are found to have any risk factors for hepatitis B. Follow your doctor's dosing instructions very carefully.
You should be current on all vaccines before you start using ofatumumab. Tell your doctor if you have received any vaccines within the past 4 weeks.
Tell your doctor if you are pregnant or planning to become pregnant.
Kesimpta may harm an unborn baby. Use effective birth control to prevent pregnancy while using Kesimpta, and for at least 6 months after your last dose.
If you use ofatumumab while you are pregnant, make sure any doctor caring for your new baby knows that you used the medicine during pregnancy. Being exposed to ofatumumab in the womb could affect your baby's vaccination schedule during the first 6 months of life.
It may not be safe to breastfeed while using ofatumumab. Ask your doctor about any risk.
How is ofatumumab given?
Your doctor will perfor...
